| Humoral-Targeted Immunotherapies in Multiple Sclerosis. | |
| | |
MedLine Citation:
|
PMID: 23208729 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
The continuous improvements of our understanding of the pathophysiological changes that occur in multiple sclerosis (MS) have translated into many novel therapeutic agents at different stages of development. These agents target more specifically the innate or the adaptive immune response. We will review agents available or under development that target the humoral pathways of the adaptive immune response. As such, humoral targeted immunotherapies that are being developed for MS are discussed herein: rituximab, ocrelizumab, and ofatumumab show promise as B-cell depleting agents. Other agents, such as atacicept were suspended during development in MS due to increased inflammatory activity versus the placebo. Although most agents were tested in relapsing-remitting forms of MS, rituximab and ocrelizumab have both been studied in progressive MS, whereas ocrelizumab only is currently moving forward in primary progressive MS trials. We provide an overview of agents available and under development that target the humoral response and include their mechanisms of action, safety profiles, and results of clinical trials. |
| | |
Authors:
|
Sabeen Lulu; Emmanuelle Waubant |
Related Documents
:
|
23251389 - Wogonin induced calreticulin/annexin a1 exposure dictates the immunogenicity of cancer ... 22951229 - Biostatic activity of piscine serum and mucus on myxozoan fish infective stages. 23072749 - Immunologic privilege in the central nervous system and the blood-brain barrier. 23404459 - Cytotoxic effect of gambogic acid on sh-sy5y neuroblastoma cells is mediated by intrins... 11032359 - U373-mg response to interleukin-1beta-induced oxidative stress. 23507439 - Plasmids expressing porcine interferon gamma up-regulate pro-inflammatory cytokine and ... 67339 - Depressed lymphocyte function after bereavement. 19380879 - Bax activation by the bh3-only protein puma promotes cell dependence on antiapoptotic b... 8637709 - Bcl-2 and adenovirus e1b 19 kda protein prevent e1a-induced processing of cpp32 and cle... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-12-4 |
Journal Detail:
|
Title: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics Volume: - ISSN: 1878-7479 ISO Abbreviation: Neurotherapeutics Publication Date: 2012 Dec |
Date Detail:
|
Created Date: 2012-12-4 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101290381 Medline TA: Neurotherapeutics Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
UCSF Multiple Sclerosis Center, San Francisco, CA, 94158, USA, sabeen.lulu@ucsf.edu. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Neuroimaging in Mitochondrial Disorders.
Next Document: A molecular photovoltaic system based on Dawson type polyoxometalate and porphyrin formed by layer-b...